Page last updated: 2024-09-03

imatinib mesylate and Arthritis, Psoriatic

imatinib mesylate has been researched along with Arthritis, Psoriatic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baeten, D; Caňete, JD; Gofita, I; Noordenbos, T; Tak, PP; van de Sande, M; Yeremenko, N	1
Schwetz, BA	1

Other Studies

2 other study(ies) available for imatinib mesylate and Arthritis, Psoriatic

Article	Year
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis and rheumatism, 2012, Volume: 64, Issue:1 Topics: Adult; Aged; Arthritis, Psoriatic; Arthritis, Rheumatoid; Benzamides; Cell Degranulation; Cells, Cultured; Female; Gene Expression; Humans; Imatinib Mesylate; Interleukin-17; Male; Mast Cells; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Messenger; Spondylarthritis; Synovial Fluid; Synovial Membrane; Synovitis; Young Adult	2012
From the Food and Drug Administration. JAMA, 2002, Mar-06, Volume: 287, Issue:9 Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Arthritis, Psoriatic; Benzamides; Chemical and Drug Induced Liver Injury; Cyclohexanones; Enzyme Inhibitors; Etanercept; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoglobulin G; Infant; Liver Failure; Nitrobenzoates; Orphan Drug Production; Piperazines; Pyrimidines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Triazoles; Tyrosinemias; United States; United States Food and Drug Administration	2002

Article

Year

Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.

Arthritis and rheumatism, 2012, Volume: 64, Issue:1

Topics: Adult; Aged; Arthritis, Psoriatic; Arthritis, Rheumatoid; Benzamides; Cell Degranulation; Cells, Cultured; Female; Gene Expression; Humans; Imatinib Mesylate; Interleukin-17; Male; Mast Cells; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Messenger; Spondylarthritis; Synovial Fluid; Synovial Membrane; Synovitis; Young Adult

2012

From the Food and Drug Administration.

JAMA, 2002, Mar-06, Volume: 287, Issue:9

Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Arthritis, Psoriatic; Benzamides; Chemical and Drug Induced Liver Injury; Cyclohexanones; Enzyme Inhibitors; Etanercept; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoglobulin G; Infant; Liver Failure; Nitrobenzoates; Orphan Drug Production; Piperazines; Pyrimidines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Triazoles; Tyrosinemias; United States; United States Food and Drug Administration

2002